acute bronchitis' are quoted in the article by Anderson and colleagues,2 I hope you will permit me to comment on its contents and conclusions.
There is no explanation in the article as to why the authors selected a dose of 4 g per day of ampicillin for their study. That this was unnecessarily large should have been evident from three articles published from this unit. [3] [4] [5] In these double-blind controlled comparisons of ampicillin with various other antibacterial agents in acute on chronic bronchitis the mean times for clearance of sputum purulence were 3S5 and 3 9 days respectively with 1 Sir,-Dr Grant's comments are entertaining but lack logic. The dose of ampicillin of 4g daily was based upon the demonstration by May and Delves' that ampicillin Ig and 2 g daily gave sputum ampicillin levels likely to achieve bacteriostatic levels in only one-quarter and one-half of patients respectively. These dosage schedules would certainly not achieve bactericidal levels, and May and Delves found that after treatment with 1 g and 2 g a high proportion of patients still had purulent sputum or grew Haemophilus influenzae. We have always used 4 g daily as our standard treatment of acute exacerbations of chronic bronchitis. In separate trials Dr Grant's group have shown similar times to achieve clearance of sputum purulence with 1 g and 2 g of ampicillin, but he really cannot assume that the result would be the same with 4 g. It is not permissible to compare his results with ours because our patients might have been more ill and with initially more purulent sputum. As he correctly states, we were careful to indicate that the conclusions only applied to the doses studied. So much for scientific argument but Dr Grant proceeds to use this shaky logic as a foundation to attack the pharmaceutical industry. His final paragraph is frankly offensive to a group of professional colleagues. The best refutation is the conclusion that ampicillin, whose manufacture is no longer protected by patent, is as good as amoxycillin. This result was a commercial disappointment to the firm concerned, yet the results were provided very quickly and they gave me every help with the study. Twenty-four patients admitted to hospital and found to have greater than 50% pus in the sputum were treated randomly with either ampicillin 1 g qds or amoxycillin 500 mg qds for 10 days. The drugs were contained in plain capsules and administered doubleblind.
Patients were recruited regardless of diagnosis but excluded if (i) they were receiving oral corticosteroids, (ii) sputum culture showed bacterial resistance, or (iii) they had a known drug allergy.
Initial clinical assessment of severity was made in conjunction with changes on the chest radiograph. Sputum purulence was measured using a simple scale according to the estimated percentage of pus in the first 24-hour specimen. Four gradings were used from "trace" to "mucopurulent" (MP) +++, and 24-hour sputum specimens were examined on each of the 10 days by the same physician. Patients were examined daily and questioned about skin and gastrointestinal symptoms.
On day 10 a final clinical assessment was made and the initial investigations repeated. Patients were then issued with a special one-month diary card and instructed to estimate their sputum purulence from day to day and also note any symptoms or requirement for further antibiotic treatment.
The two groups were comparable on the basis of age, smoking habits, initial sputum purulence, fever, FEV1, 24-hour sputum volumes, and final diagnosis. 
